702 Results

People

  1. Motzer
    Motzer
  2. Livingston
    Livingston
  3. Norton
    Norton
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Krown
    Krown
  7. Sepkowitz
    Sepkowitz
  8. O'Reilly
    O'Reilly
  9. Panageas
    Panageas
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)
  7. Epidemiology and Biostatistics (73)
  8. GSK Faculty (73)
  9. Division of Subspecialty Medicine (65)
  10. Gastrointestinal Oncology Service (64)
  1. "fever"
Formats
  1. Journal Article (657)
  2. Review (23)
  3. Conference Paper (6)
  4. Research Letter (6)
  5. Guidelines (5)
  6. Editorial (4)
  7. Correspondence (1)
Groups
  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)

More Groups

People
  1. Robert Motzer (24)
  2. Larry Norton (20)
  3. Philip Livingston (19)
  4. Carol Aghajanian (17)
  5. Clifford Hudis (17)
  6. Kent Sepkowitz (17)

More People

Years
  1. 2025 (21)
  2. 2024 (42)
  3. 2023 (40)
  4. 2022 (22)
  5. 2021 (25)
  6. 2020 (44)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Clinical Cancer Research (33)
  3. Blood (22)
  4. Lancet Oncology (22)
  5. Cancer (21)
  6. New England Journal of Medicine (18)

More Publications

Publishers
  1. Elsevier Inc. (107)
  2. American Society of Clinical Oncology (70)
  3. Elsevier Science, Inc. (55)
  4. Springer (53)
  5. Nature Publishing Group (40)
  6. Wiley Blackwell (38)

More Publishers

Results (702)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: A subgroup analysis of the phase 3 KEYNOTE-045 trial
    Journal Article

    Nishiyama, H.; Yamamoto, Y.; Sassa, N.; Nishimura, K.; Fujimoto, K.; Fukasawa, S.; Yokoyama, M.; Enokida, H.; Takahashi, K.; Tanaka, Y.; more...
    International Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
    Journal Article

    Sehn, L. H.; Herrera, A. F.; Flowers, C. R.; Kamdar, M. K.; McMillan, A.; Hertzberg, M.; Assouline, S.; Kim, T. M.; Kim, W. S.; Ozcan, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-1 blockade in advanced adrenocortical carcinoma
    Journal Article

    Raj, N.; Zheng, Y.; Kelly, V.; Katz, S. S.; Chou, J.; Do, R. K. G.; Capanu, M.; Zamarin, D.; Saltz, L. B.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: A multicenter phase II study
    Journal Article

    Khodadoust, M. S.; Rook, A. H.; Porcu, P.; Foss, F.; Moskowitz, A. J.; Shustov, A.; Shanbhag, S.; Sokol, L.; Fling, S. P.; Ramchurren, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Trans biliary proximal and distal coil embolization of an arteriobiliary fistula: Report of a case and review of literature
    Review

    Galambo, F.; Maybody, M.
    CVIR Endovascular (2019)

    Fulltext@MSK | Save
  • Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations
    Journal Article

    Hyman, D. M.; Tran, B.; Paz-Ares, L.; Machiels, J. P.; Schellens, J. H.; Bedard, P. L.; Campone, M.; Cassier, P. A.; Sarantopoulos, J.; Vaishampayan, U.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials
    Editorial

    Basch, E.; Leahy, A. B.
    Clinical Trials (2019)

    Fulltext@MSK | Save
  • Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation: An open-label, single-arm cohort of the histology-independent VE-Basket study
    Journal Article

    Subbiah, V.; Gervais, R.; Riely, G.; Hollebecque, A.; Blay, J. Y.; Felip, E.; Schuler, M.; Gonçalves, A.; Italiano, A.; Keedy, V.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation–positive relapsed or refractory low-grade glioma: Results from a phase I/IIa study
    Journal Article

    Hargrave, D. R.; Bouffet, E.; Tabori, U.; Broniscer, A.; Cohen, K. J.; Hansford, J. R.; Geoerger, B.; Hingorani, P.; Dunkel, I. J.; Russo, M. W.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
    Journal Article

    Higano, C. S.; Armstrong, A. J.; Sartor, A. O.; Vogelzang, N. J.; Kantoff, P. W.; McLeod, D. G.; Pieczonka, C. M.; Penson, D. F.; Shore, N. D.; Vacirca, J.; more...
    Cancer (2019)

    Fulltext@MSK | Save